Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HATCHeT: Elbasvir/Grazoprevir in HCV Patients with HCC
NCT04546802Phase 3Withdrawn
- Start
- Sep 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of elbasvir, grazoprevir in hepatitis C (HCV). Planned start Sep 2019; status: withdrawn.
02
Drugs
elbasvirgrazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04546802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04546802.